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Abstract Various strategies have been published enabling
cardiomyocyte differentiation of human induced pluripotent
stem (iPS) cells. However the complex nature of signaling
pathways involved as well as line-to-line variability compro-
mises the application of a particular protocol to robustly obtain
cardiomyocytes from multiple iPS lines. Hence it is necessary
to identify optimized protocols with alternative combinations
of specific growth factors and small molecules to enhance the
robustness of cardiac differentiation. Here we focus on sys-
tematic modulation of BMP and WNT signaling to enhance
cardiac differentiation. Moreover, we improve the efficacy of
cardiac differentiation by enrichment via lactate. Using our
protocol we show efficient derivation of cardiomyocytes from
multiple human iPS lines. In particular we demonstrate car-
diomyocyte differentiation within 15 days with an efficiency
of up to 95 % as judged by flow cytometry staining against
cardiac troponin T. Cardiomyocytes derived were functionally
validated by alpha-actinin staining, transmission electron mi-
croscopy as well as electrophysiological analysis. We expect
our protocol to provide a robust basis for scale-up production
of functional iPS cell-derived cardiomyocytes that can be used
for cell replacement therapy and disease modeling.
Keywords Human iPS cells . Cardiac differentiation .WNT
signaling . BMP signaling . Lactate enrichment .
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Introduction
In spite of recent advances in medicine cardiovascular disorders
remain a major cause of mortality in the world [1]. Supply with
human cardiomyocytes is generally limited due to lack of
donors as well as the restricted proliferation rate of adult
cardiomyocytes. Thus, with respect to use human
cardiomyocytes for regenerative therapies, drug toxicity studies
as well as disease modeling alternative sources are highly
desired. There have been many attempts in this direction using
adult stem cells such as bone marrow derived stem cells
(BMSCs) [2], mesenchymal stem cell (MSCs) [3], c-kit and
isl-1 positive cardiac stem cells (CSCs) [4, 5]. However there is
little evidence that BMSCs and MSCs differentiate into
cardioymocytes after transplantation since positive effects ob-
served using those cells are mainly due to angiogenesis and
paracrine effects [6]. Although it has been shown that CSCs can
be differentiated into all cardiovascular lineages in an animal
model [7], in humans there have been rare studies due to lack of
donors, limited in vitro amplification as well as complicated
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isolation procedures of the CSCs [6, 8]. Embryonic stem (ES)
cells hold great promise for providing an unlimited source of
cardiac cells since ES cells self-renew indefinitely in cell culture
and are able to differentiate into any somatic cell type [9].
However ethical considerations associated with the use of
human embryos might represent a roadblock for clinical appli-
cation [10]. Major breakthrough in this field came when
Yamanaka and colleagues showed that overexpression of four
transcription factors namely Oct-4, Sox2, Klf-4 and c-Myc
were able to transform somatic cells into induced pluripotent
stem cells (iPS) [11]. iPS technology allows generation of
pluripotent stem cells from any somatic cells. Not only it
overcomes ethical concerns associated with ES cells but also
offers the potential of autologous transplantation since patient-
specific cells can be used for cellular reprogramming [11].
Numerous protocols have been published reporting the der-
ivation of cardiomyocyte-like cells from human ES and iPS
cells. Induction of differentiation by co-culture with stroma cells
has been demonstrated [12] as well as the use of embryoid body
(EB) based differentiation paradigms [13, 14]. It is similar to
embryonic development in some respect and cells from all three
germ layers are formed during the course of differentiation.
However EBs have complex microenvironments and for this
reason signaling pathways are difficult to modulate explaining
poor efficiency of cardiac differentiation [15].Moreover, there is
a significant line-to-line variability with respect to the method of
reprogramming used and iPS quality resulting in up to 100-fold
differences in lineage specific gene expression amongst the lines
treated with same protocols [16]. Such variability within a broad
range of pluripotent cell lines greatly limits its application [17,
18]. Several approaches have been published utilizing monolay-
er culture of cells in a serum free condition having growth
factors such as BMP4, Activin A, FGF2, VEGF in order to
increase the efficiency while reducing the heterogeneity arising
during EB based differentiation [19–21]. However, it has been
shown that optimal concentrations of growth factors greatly vary
among different iPS lines. A study by Kattman et al. as well as
follow up report by Sa et al. systematically showed different
requirements of Activin A and BMP4 concentration for efficient
cardiomyocytes yield amongst different pluripotent cell lines
[22, 23]. Thus, robust and efficient cardiac differentiation re-
quires the optimization of the protocol for each individual line,
which makes it laborious [24].
Recent advances in cell signaling studies have shed light on
detailed signaling pathways involved during cardiac differentia-
tion. It has been shown that WNT signaling plays a critical role
during cardiogenesis [25]. It has been suggested that during early
embryonic differentiationWNTis required formesodermal spec-
ification, however, later on cardiac specification is hampered by
WNT signaling and thus inhibition of WNT signaling might be
necessary for the formation of cardiomyocytes [26]. Recent
studies have shown the use of WNT inhibiting small molecules
for increasing the cardiomyocyte yield in the case of EB [27] as
well as monolayer-based protocols [28, 29]. Moreover, two
recent studies by Cao et al. have shown importance of ascorbic
acid in increasing the cardiac differentiation efficiency by affect-
ing MEK/ERK pathway. By combining the application of
BMP4, CHIR99021 and ascorbic acid they were successful in
isolation of cardiovascular cells from human pluripotent stem
cells [30, 31]. However, varied differentiation propensities of
multiple pluripotent cell lines to a particular protocol require
more alternative approaches. Hence, still it is highly desired to
devise simple and efficient protocols to achieve high robustness
and efficacy. Here we show improvement in cardiac differentia-
tion efficiency using precise modulation of WNT and BMP
signaling. We identify an optimal combination of concentrations
of BMP4 and CHIR99021 and finally perform cardiomyocyte
enrichment by lactate supplementation [32]. By that within
15 days we achieve generation of more than 90 %
cardiomyocytes as judged by cardiac Tropononin Tstaining with
unmatched low line-to-line variability.
Materials and Methods
Human iPSC Cultivation and Subsequent Cardiac
Differentiation
Human iPSC were maintained on hESC-qualified Matrigel(TM)
(BD Biosciences) coated plates in mTESR1 (STEMCELL
Technologies) medium until they reached 80 to 90% confluency.
Cardiac differentiation was induced by BMP4 (Life technologies)
(25 ng/ml) and CHIR99021 (5 μM) (Sigma-Aldrich) in
RPMI1640 (Life technologies) medium containing B27 (Life
technologies) and 2 mM glutamine (Life technologies) and
50 μg/ml L-Ascorbic acid (Cell culture tested powder; Sigma-
Aldrich) as a basalmedium.After 24 h cells were kept in the same
basal medium with CHIR (5 μM) only for 18–36 h. Afterwards
cells were kept in RPMI basal medium with B27 without insulin
for 24 h then medium was replaced with similar basal medium
havingWNT inhibitor either 10μMofXAV939 (Sigma-Aldrich)
or IWR1 (Sigma-Aldrich) for 5 days. Afterwards cells were kept
4 to 5 days in basal medium (B27 + insulin) followed by
replacement with cardiac enrichment medium (RPMI 1640 with-
out glucose (Life technologies) + 4 mM sodium L-lactate [32]
(Sigma-Aldrich). Cells were kept in enrichment medium for 4 to
5 days. After enrichment phase medium was switched back to
basal medium (RPMI + B27 + glutamine).
Cell Lines
del-AR1034ZIMA 001 and fl-AR1034ZIMA 001 are
lentiviral reprogramming derived iPS sister clones from human
dermal fibroblasts (del: transgene excised, fl: transgene floxed
[33]. Human iPS cell line (k-hiPS) [34] is a lentivirally derived
iPS cell line from human keratinocytes kindly gifted by Dr.
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Stefan Liebau fromUniversity of Tübingen, Germany. Human
iPS cell line iLB-C-50-s9 is a Sendai virus derived iPS cell line
from human cord blood cells. Human iPS cell line iLB-C1-
30 m-r12 is a retroviral reprogramming derived iPS cell line
from human dermal fibroblasts cells [35]. As WNT reporter
cell line we used a neural stem cell line (I3 lt-NES) carrying the
7TGP WNT reporter construct developed by Fuerer & Nusse
(2010) [36] and obtained via Addgene (#24305).
Immunostaining
For cardiomyocyte characterization, immunostaining was per-
formed using anti-cTNT (Abcam; 1:100) and anti-alpha-actinin
(Sigma-Aldrich; 1:200) as primary antibodies and Alexafluor-
488-cojugated anti-mouse IgG as a secondary antibody. Briefly,
cells were washed with PBS (Life technologies), fixed with 4 %
PFA (Sigma-Aldrich) for 15 min and permeabilized in PBS
containing 0.1 % Triton X-100 (Sigma-Aldrich) and 5 % FCS
(Life techologies) for 30 min. Cells were then incubated over-
night with the primary antibodies. Next day, secondary antibody
Alexafluor-488-cojugated anti-mouse IgG (1:1,000; Life tech-
nologies) were used to detect and visualize the primary antibod-
ies. All antibodies were diluted in blocking solution. Similar
protocol was also used for the staining using ISL1 (Biorbyt;
1:200) antibody. Micrographs were taken with an Axiovert
200 M microscope (Carl Zeiss).
RT-PCR
Total RNA was prepared with the NucleoSpin RNA kit
(Macherey -Nagel) and treated with DNase (Thermo
Scientific). RNA (1 μg) was reverse transcribed into cDNA
via Oligo (dT) with SuperScript III Reverse Transcriptase
(Invitrogen). PCR was perfomed using Go Taq polymerase
kit (Promega) with following conditions; 95 °C for 2 min;
followed by 34 cycles of 94 °C for 30 s, 60 °C for 30 s, and
72 °C for 45 s; followed by a single cycle of 72 °C for 5 min
using the primers [37] given below.
Primers Band size (bp) Tm (0C)
Oct4-F: aac ctg gag ttt gtg cca ggg ttt 120 60
Oct4-R: tga act tca cct tcc ctc caa cca
Tbrachyury-F: tgt ccc agg tgg ctt aca gat gaa 140 60
Tbrachyury-R: ggt gtg cca aag ttg cca ata cac
ISL1-F: cac aag cgt ctc ggg att gtg ttt 200 60
ISL1-R: agt ggc aag tct tcc gac aa
Nkx2.5-F: gcg att atg cag cgt gca atg agt 220 60
Nkx2.5-R: aac ata aat acg ggt ggg tgc gtg
cTNT-F: ttc acc aaa gat ctg ctc ctc gct 160 60
cTNT-R: tta tta ctg gtg tgg agt ggg tgt gg
β-actin (BA)-F: ttt gaa tga tga gcc ttc gtc ccc 130 60
β-actin (BA)-R: ggt ctc aag tca gtg tac agg
taa gc
Flow Cytometry
1×106 cells were trypsinized and fixed with 4 % PFA for
10 min. Cells were then washed with PBS, permeabilized in
PBS containing 0.1 % Triton X-100 and 5 % FCS for 30 min
and incubated for 2 h with cTNT antibody (Abcam; 1:100).
No antibody was taken as a negative control. Cells were then
washed once with PBS containing 0.1 % Tween-20 and re-
suspended in PBS containing 0.1 % Triton-X 100 and 5 %
FCS and secondary antibody Alexafluor-488-cojugated anti-
mouse IgG (1:1,000; Life technologies) for 1 h in dark.
Finally, cells were washed again with PBS containing 0.1 %
Tween-20 and measured for FACS analysis. Analysis was
performed by Flow Jo program.
Whole-Cell Calcium Current Measurements
Conventional whole-cell patch clamp recordings were per-
formed at room temperature in bath solution containing
(mM): NaCl 137, CsCl 5.4, CaCl2 2, MgCl2 1, glucose 10,
HEPES 10 (pH 7.4 with NaOH). Borosilicate pipettes (2–3
MΩ) were filled with a solution containing (mM): CsCl 120,
MgCl2 1, Mg-ATP 4, EGTA 10, HEPES 5 (pH 7.2 with
CsOH). Giga-Ohm seals were formed by gentle suction.
Membrane capacitance was automatically displayed in the
pClamp 10.2 software (Axon instruments). Cells were
depolarized from a holding potential of −80 mV to −40 mV
for 45 ms in order to inactivate sodium channels. This
prepulse was followed by test voltages ranging from −40 to
+50 mV in 10 mV steps (pulse duration 150 ms) with a 3 s
interval between single pulses.
Calcium Imaging
Calcium imaging was performed in cell cultures loaded with
5µM of calcium indicator dye fluo-4AM (Life technologies).
Briefly, the cells were cultivated in 6 well plates and incubated
then with 1 ml of loading dye solution containing fluo-4 AM
at room temperature for 20 min in the dark. Movies were
captured through the Keyence Microscope BZ-9000
(Keyence, Japan)
Action Potential and Ramp Recordings
Cardiomyocytes were enzymatically dissociated at day 30 and
plated at low density on glass cover slips coated with fibro-
nectin. Action potentials and voltage ramps from −100 mV to
60 mV, 250 ms long were recorded on spontaneously beating
cardiomyocytes with a EPC 10 amplifier (Heka Electronics)
as previously described [38]. Electrode resistance was be-
tween 2.5 and 3.5 MΩ, the pipette solution contained (in
mM): 50 KCl; 80 KAsparatate; 10 EGTA; 10 Hepes; 3
MgATP; 1 MgCl2 (pH 7.2) and the extracellular solution
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contained (in mM): 140 NaCl; 5.4 KCl; 1.8 CaCl2; 1 MgCl2;
10 Hepes; 10 Glucose (pH 7.4).
Transmission Electron Microscopy
Undifferentiated iPS cells or differentiated iPS cells at day 21
were fixed in 4.5 % glutaraldehyde in 0.1 M phosphate buffer
pH 7.2 (PB). After washing with 0.1 M PB, specimens were
subsequently fixed for 1 h with 1 % osmiumtetroxide in PB
and washed with water. Specimens were then dehydrated in
ascending concentrations of ethanol including en-bloc con-
trasting using 2 % uranylacetate in 70 % ethanol for 1 h.
Subsequently, they were embedded in Epon812 and used for
preparation of ultrathin sections which were poststained with
2 % uranylacetate and 0, 2 % lead citrate. The sections were
observed using a LEO AB 912 transmission electron micro-
scope (Zeiss NTS, Oberkochen, Germany)
Results
Defining Optimal Window of WNT Modulation to Achieve
Efficient Myocardial Induction in Human iPSCs
Since cardiomyocyte differentiation critically depends on
WNT signaling, our first step was to screen molecules with
which one can tightly control WNT signaling in iPS cells and
their progeny, both in an agonistic and antagonistic manner,
respectively. In order to quantitatively assess the level of
WNT signaling, we employed a WNT reporter cell line and
assessed the functionality of candidate molecules to modulate
WNTsignaling. In order to identify potent WNTactivator, we
used CHIR99021 (designated CHIR hereafter) and BIO. We
found that 5 μM CHIR99021 (designated CHIR hereafter)
strongly activates WNTsignaling (data not shown) while BIO
appeared toxic to the cells. To identify potent molecules with
potent WNT inhibition, we screened previously described
molecules XAV939, IWR1, KY02111 and WNT-C59.
According to this analysis XAV939 and IWR1 showed stron-
gest WNT inhibition without causing excessive cell death.
Hence we decided to use CHIR as WNT activator and
XAV939 or IWR1 as WNT inhibitor during the subsequent
experiments. In order to achieve efficient cardiovascular in-
duction we decided to formulate different combinations of
growth factors and small molecules modulating important
signaling pathways such as TGFβ (Activin A, BMP4) and
FGF (FGF2) as well as WNT (CHIR, XAV939, IWR1) [15].
As a quick read out for cardiovascular induction we decided to
check the expression of T-brachyury at day two (Fig. 1a) and
Isl1 at day 5 (Fig. 1b) of differentiation. As an end-point
analysis we monitored the capability of cultures to exhibit
spontaneously beating patches in a semi-quantitative manner
(Suppl. Tabl. 1-3). Comprehensive quantification of cardiac
differentiation was carried out by flow cytometry analysis
using cTNT specific antibodies (Fig. 1c). According to these
analyses we found that the combination of BMP4 (25 ng/ml)
and CHIR (5 μM) strongly enhanced expression of T-
brachyury whereas additional application of Activin A had
no effect (Fig. 1a). Neither increasing the CHIR concentration
nor extending the incubation period beyond 48 h had a ben-
eficial effect (Suppl. Tabl. 1). Applying 25 ng/ml BMP4
turned out to be the optimal concentration since higher and
lower concentrations, respectively, reduced the number of
beating patches (Suppl. Tabl. 2). After an initial phase of
WNT activiation the precise timing of WNT inhibition is
critical. Our data shows that application of both WNT inhib-
itors, XAV939 or IWR1, between day 3 and 8 results in
optimal cardiac differentiation (Suppl. Tabl. 3). After day 5
of differentiation cells showed strong expression of the early
cardiac marker ISL1 in almost every cell (Fig. 1b). Using
these optimized conditions we generated cardiomyocyte-like
cells of up to 95 % purity from human iPS line (iLB-C-50-s9)
at day 12 of differentiation as judged by flow cytometry
analysis using cTNT specific antibodies (Fig. 1c).
Lactate Based Cardiac Enrichment Strongly Reduces
Line-to-Line Variability of Cardiomyocyte Differentiation
After optimization of cardiac differentiation using a standard
iPS line, we checked the efficacy of the devised protocol on
multiple iPS lines representing different origins of cells (fi-
broblasts, keratinocyte and cord blood cells) as well as
methods of reprogramming (Retrovirus, Lentivirus and
Sendai virus) to cover the full spectrum of state-of-the-art
iPS technology (see details on iPS lines used in the materials
section). Although our optimized protocol gave rise to a
highly enriched population of beating cells with the standard
iPS cell line (del-AR1034ZIMA 001), the outcome with the
other iPS lines indeed varied substantially. In fact, we obtained
yields of cTNT-positive cells ranging from 33 to 92 %
(Fig. 2a) demonstrating the high line-to-line variability using
the basic standard protocol. In order to maximize purity of
cardiomyocytes from different iPS lines to the same level, we
decided to apply lactate based cardiac enrichment in the late
phase of our protocol. As has been recently reported glucose-
depleted, lactate-supplemented culture medium strongly se-
lects for cardiomyocytes [32]. Since only cardiomyocytes can
metabolize lactate for energy supply, other non-cardiac cells
were expected to die out during this 4 days treatment resulting
in higher purity of cardiomyocytes. In order to achieve this,
we switched the medium at day 12 of cardiac differentiation to
basal medium without glucose but supplemented with
lactate. In fact when we applied lactate enrichment, we could
obtain 95% pure cTNT-positive cells from the iPS line iLB-C-
30-r12 which otherwise gave about 63 % positive
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cardiomyocytes (Fig. 2a and b). Even the iPS line fl-
AR1034ZIMA, carrying loxP-flanked reprogramming
transgenes [35] and being strongly resistant towards cardiac
differentiation, showed efficient enrichment from 34 to 74 %
cTNT-positive cells (Fig. 2a).
In conclusion our optimized protocol of cardiomyocyte
differentiation from multiple human iPS lines represents a
three phase protocol consisting of cardiac induction, specifi-
cation and enrichment as outlined in Fig. 3a. During the
induction phase iPS cells are treated with our formulation
(BMP4 and CHIR) in a basal medium with insulin, which
resulted in strong upregulation of the mesendodermal marker
T-brachyury (Fig. 3b). Induction phase is followed by treat-
ment with WNT inhibitors in basal medium devoid of insulin
in order to achieve proper specification to cardiac mesoderm,
which is confirmed by expression of early and late cardiac
precursor markers ISL1 and Nkx2.5, respectively (Fig. 3b).
Cells then further mature into beating cardiomyocytes ex-
pressing the mature cardiomyocyte marker cTNT (Fig. 3b).
Once beating is observed cells are switched to basal medium
with insulin followed by enrichment phase with basal medium
devoid of glucose but supplemented with 4 mM lactate for
4 days (Fig. 3a).
Characterization and Validation of Cardiomyocytes Derived
from Human iPSCs
We performed a series of standard immunohistochemical and
electrophysiological methods to assess the functionality of
cardiomyocyte derived. Obtained cardiomyocytes showed
strong cardiac specific alpha-actinin staining with typical stri-
ation pattern as well as cTNT staining (Fig. 3c). Moreover,
patch-clamp recordings on single beating cardiomyocytes
showed typical spontaneous action potentials (Fig. 3d),
with atrial (n=2) or ventricular (n=4)-like properties, as well
as characteristic voltage-dependent inward and outward
currents using voltage ramps (Fig. 3e). We recorded Ca2+
currents typical for L-type Ca2+ channels with a half-
maximum activation at −13.69±0.97 mV, a maximum current
density of −11.55±1.6 pA/pF at 0 mV and nearly complete
Fig. 1 Optimization of myocardial induction of human iPS line (iLB-C-
50-s9). a RT PCR analysis to assess the expression of T brachyury at day
2 of cardiac induction using different conditions, namely Ch, B + Ch and
A + B + Ch b Immunostaining using cardiac precursors maker ISL1 at
day 5 of cardiac differentiation using small molecule combination (B +
Ch). Scale bar: 100 μM c Flow cytometry analysis of cardiac-specific
troponin T staining at day 15 of cardiac differentiation showed 21.4 and
92.5 % of cTNT positive cells in the case of only CHIR99021/XAV939,
and a combination of BMP4 with CHIR99021/XAV939, respectively.
Abbreviations: T T-brachyury, BA beta-actin, Ch CHIR99021, B BMP4,
A Activin A, NC negative control; cTNT cardiac troponin T
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inactivation during 150 ms of depolarization (n=4) (Fig. 3f
and g). In addition calcium imaging was performed using the
fluorescent Ca2+ indicator Fluo-4 AM. Fluo-4 AM fluores-
cence intensity sparks indicates binding of calcium to fluo-4
upon release of calcium from the sarcoplasmic reticulum in
hiPS derived cardiomyocytes. Fluo-4 fluorescence intensity
sparks were recorded using fluorescence microscopy
(Supplementary movie S2).
Ultra-Structural Analysis of iPS Cell-Derived
Cardiomyocytes
In order to study the maturation state of iPS-derived cardio-
myocyte-like cells at ultra-structural level we performed trans-
mission electron microscopy analysis of 21 day old
cardiomyocytes. Many cells show nascent parallel arrays of
myofilament bundles anchored at Z-line like electron dense
structures (Suppl. Figure 1). They show different spatial ori-
entation within the same cell as well as branching. Moreover,
we observed sarcomer-like organization of contractile fila-
ments (Fig. 4a). Additionally, fascia adherens-like and gap-
junctions-like cellular contacts as well as initial sarcomeric
organisation of actin and myosin filaments were detected. The
sarcomeric structures of contractile filaments exhibited al-
ready identifiable A- and I-bands together with Z-lines as well
as H-zones (Fig. 4b-d, Suppl. Figure 1).
Discussion
Our study reports a novel robust strategy to obtain
cardiomyocytes from diverse human iPS lines that originate
from a wide spectrum of state-of-the-art reprogramming
Fig. 2 Enrichment of cardiomyocytes with sodiumL-lactate. a Summary
of cardiac differentiation of different human iPS lines using efficient
cardiac differentiation followed by lactate enrichment. b Flow cytometry
analysis of cardiac-specific troponin T staining at day 16 of cardiac
differentiation of line iLB-C1-30 m-r12 showed about 63 % cTNT
positive cardiomyocytes without lactate enrichment and 96 % cTNT
positive cells after lactate enrichment
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technology using an optimal combination of well-orchestrated
extrinsic stimuli such as BMP4 and CHIR followed by WNT
inhibition using XAV939 or IWR1 and enrichment of
cardiomyocytes by supplying lactate as an energy source.
The protocol described herein divides the whole differentia-
tion process into three phases, namely cardiovascular induc-
tion, cardiac specification and cardiomyocyte enrichment. Our
analysis revealed that efficient cardiac induction requires ap-
propriate concentrations as well as precise timing of the right
window of application of each chemical. We found out that
sequential application of each chemical, BMP4 and CHIR,
respectively, for up to two days is sufficient to drive the cells
into cardiovascular fate which is consistent with earlier studies
[28, 29, 31, 42]. Notably, we have used basal media with
insulin during first two days of induction phase. Previous
studies have reported use of basal medium without insulin
during cardiac differentiation due to its negative influence on
cardiac specification of early mesoderm [28, 39]. However,
our study shows that using basal mediumwithout insulin from
the beginning appears very stressful to the cells. Hence we
decided to keep insulin for the initial two days and remove it
during the specification phase in order to minimize cell death
and its negative influence on cardiac specification. In order to
achieve cardiac specification of early mesoderm, we used
inhibitors of WNT signaling for up to 4 days as described in
earlier studies [28, 29]. We performed a comparative valida-
tion of molecules exhibiting WNT inhibitory activity using a
WNT reporter cell line. It turned out that amongst four differ-
ent compounds tested, XAV939 showed the strongest WNT
inhibitory effect and was therefore used for all differentiation
Fig. 3 Characterization of human iPSC (del-AR1034ZIMA001) derived
cardiomyocytes. a Scheme of efficient cardiac differentiation of human
iPSC with combination of strong cardiac induction in early phase and
cardiac enrichment in late phase. b RT-PCR analysis for mesendoderm,
mesoderm, and cardiac specific gene expression c Immunohistochemical
characterization of hiPS-derived cardiomyocytes using antibody against
alpha-actinin (top) and cardiac troponin T (bottom). Scale bar: 40 μm. d
Action potential recorded from a ventricular like cardiomyocyte. e
Typical activation of voltage dependent inward and outward currents
following a ramp protocol in voltage clamp (-100 to +60 mV in
250 ms). f Representative whole cell calcium current recording (2 mM
extracellular Ca2+). Cells were depolarized from a holding potential of -80
to -40mV for 45ms in order to inactivate sodium channels. This prepulse
was followed by test voltages ranging from -40 to +50mVin 10mV steps
(pulse duration 150 ms). (G) Whole cell calcium current density-voltage
relationship (n=4)
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experiments. Moreover, we also achieved the same cardiac
differentiation efficiency with previously described WNT in-
hibitor IWR-1 [27]. We observed different cardiac differenti-
ation efficiencies in multiple iPS lines presumably due to the
complexity of the signals, which is in accordance with recent
studies [17, 18]. We therefore elaborated further purification
steps to improve the yield of cardiomyocytes with reduced
line-to-line variability. We decided to assess the potential of
lactate enrichment of cardiomyocytes and show a substantial
cardiac enrichment of an iPS line (iLB-C1-30 m-r12) that
exhibited relatively poor cardiomyocyte yield using our opti-
mized chemical cocktail only. This indicates that the combi-
nation of extrinsically induced differentiation stimuli together
with metabolic enrichment is an efficient means to overcome
line-to-line variability of cardiomyocyte differentiation. There
are various published studies showing successful cardiac dif-
ferentiation of human pluripotent stem cells. However, as
depicted in supplementary table 4 three key features separates
our protocol from others i.e. i) sequential treatment of cardiac
inducing factor with a clearly defined time window together
with ii) an insulin switch, which in our experience is very
critical to get reproducible results; iii) in addition our protocol
includes a rapid and efficient way to enrich the cardiac pop-
ulation with lactate supplement. In order to evaluate the func-
tional properties of cardiomyocytes, comprehensive valida-
tion was not only carried out at protein level by alpha-actinin
and cTNT stainings but also by ultra-structural analysis. TEM
results showed well organized sarcomeric structures in 21 day
old cardiomyocytes with distinct I- and A-bands indicating
relatively mature phenotype as described in earlier studies [15,
29]. Spontaneous action potentials of differentiated cells
showed typical cardiomyocyte behaviour and we identified
both ventricular and atrial-like shapes. Voltage ramps identi-
fied fast sodium, calcium as well as potassium currents.
Characteristics of Ca2+ currents obtained from iPS-derived
cardiomyocytes were similar to those recently obtained from
murine ventricular myocytes [40]. I-V relationship further-
more perfectly agreed with data from HEK293 cells express-
ing recombinant human L-type Ca2+-channels suggesting that
indeed iPS-derived cells express cardiac-like channel com-
plexes consisting of pore-forming and auxiliary subunits
[41]. Moreover calcium imaging further indicated usual
calcium current activity seen in the case of human
cardiomyocytes. In conclusion, cardiomyocytes obtained by
Fig. 4 Ultrastructural analysis of
21-day old human iPS (del-
AR1034ZIMA 001) cell-derived
cardiomyocytes. a Two cells in
close contact displaying
sarcomer-like organization of
contractile filaments. Scale bar:
1,000 nm (b–c) Higher
magnification showing the
presence of fascia adherens-like
and gap-junctions like cellular
contacts and initial sarcomeric
organisation of actin and myosin
filaments. Scale bar: b 1,000 nm,
c 250 nm. d iPS cell-derived
cardiomyocyte-like cells show
sarcomer organization of
contractile filaments with already
identifiable A- and I-bands
together with Z-lines as well as
H-zones. Abbrevations: m
mitochondria, N Nucleus, FA-lS
Fascia adherens-like structure,
GJ-lS Gap junctions-like
structure, Z Z-line, H H-zone.
Scale Bar: 250 nm
Stem Cell Rev and Rep (2015) 11:560–569 567
our protocol have the potential for stem cell based therapies,
drug toxicity as well as disease modeling studies. Hence we
expect our protocol to provide a robust basis for scale-up
production of functional iPS cell-derived cardiomyocytes.
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